This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Clinical conclusions
IFNB-1b is the only treatment that has substantially altered the natural history of MS in a properly controlled clinical trial.
Modelling
This study involved the construction of a cost-effectiveness model for IFNB-1b for relapse-remitting multiple sclerosis.
Outcomes assessed in the review
The outcomes assessed were the differences in QoL between groups of patients with MS and compared with the general population (MS-QoL & EQ-5D). Estimated changes in QoL arising from IFNB therapy.
Study designs and other criteria for inclusion in the review
There had only been one reported trial considering the effectiveness of IFNB-1b, which was a randomised, doubleblind, placebo-controlled trial. This was included in the model. Other studies considering the natural history of the disease were included for their information about disease progression probabilities.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Only one trial of IFNB-1b has been carried out.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
One study reporting the effectiveness of the drug in terms of relapse rates was used. Three other studies were used to inform disease progression probabilities.
